Specifically, germline pathogenic CHEK2 variants, excluding the low-risk variants, p.(Ile157Thr) and p.(Ser428Phe), known to be associated with much lower risk, confer an approximate lifetime risk for breast cancer diagnosis of about 25–30% in females [4,5]. Here, CHEK2 is linked to breast carcinoma.